Peiminine
CAS No. 18059-10-4
Peiminine( Verticinone | Raddeanine )
Catalog No. M18142 CAS No. 18059-10-4
Peiminine is an effective inhibitor for lung inflammation and pulmonary fibrosis in a rat model of bleomycin-induced lung injury.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 64 | In Stock |
|
| 10MG | 100 | In Stock |
|
| 25MG | 167 | In Stock |
|
| 50MG | 248 | In Stock |
|
| 100MG | 374 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePeiminine
-
NoteResearch use only, not for human use.
-
Brief DescriptionPeiminine is an effective inhibitor for lung inflammation and pulmonary fibrosis in a rat model of bleomycin-induced lung injury.
-
DescriptionPeiminine is an effective inhibitor for lung inflammation and pulmonary fibrosis in a rat model of bleomycin-induced lung injury.
-
In VitroCell Cytotoxicity Assay Cell Line:HepG2, Hela, SW480, MCF-7 Concentration:2 μg/mL, 4 μg/mL, 6 μg/mL, 8 μg/mL, 10 μg/mL, 12μg/mL, and 14 μg/mL Incubation Time:24 h, 48 h, 72 h Result:Exhibited a significant inhibition on the survival of HepG2, Hela, SW480 and MCF-7 cells with the IC50 values were 4.58, 4.89, 5.07 and 5.12 μg/mL at 24 h, respectively.Apoptosis Analysis Cell Line:HepG2 Concentration:2 μg/mL, 4 μg/mL, 6 μg/mL, 8 μg/mL Incubation Time:24 h Result:Dissociated chromosome to produce DNA fragments dose-dependently.Cell Cycle Analysis Cell Line:HepG2 Concentration:2 μg/mL, 4 μg/mL, 6 μg/mL Incubation Time:24 h Result:Decreased the percentage of G1 phases from 65.15% ± 0.78 to 49.55% ± 0.17 with the increase of concentrations. Increased the percentage of G2/M phases from 17.32% ± 0.20 to 39.99% ± 0.47 with the increase of concentrations.Western Blot Analysis Cell Line:HepG2 Concentration:2 μg/mL, 4 μg/mL, 6 μg/mL Incubation Time:24 h Result:Reduced the expression of procaspase-3, PARP1, procaspases-8 and -9, and Bcl-2 at 2-6 μg/mL.
-
In VivoAnimal Model:ulcerative colitis model Dosage:3mg/kg Administration:Intraperitoneal injection (i.p.)Result:Reduced inflammation, mucosal ulcers, involvement of digestive system layers, and infltration of inflammatory cells.Reduced the levels of MPO and NO generated in the rectal tissue.Reduced cell proliferation in spleen cell.Decreased the production of f IL-1β, IL-6, and TNF-α cytokines.Reduced expression levels of genes IL-1β, IL-6, TNF-α, iNOS, and COX2.Animal Model:Ovariectomized (OVX) rat model Dosage:10 mg/kg Administration:Intraperitoneal injection (i.p.)Result:Alleviated the bone loss caused by surgical castration.Improved the expression of COL1A1 and β-catenin and reduced the increase expression of PPAR-γ in trabecular bone.Animal Model:Allergic dermatitis model Dosage:1 mg/kg, 5 mg/kg Administration:were applied to the dorsal skin Result:Alleviated the bone loss caused by surgical castration.Improved the expression of COL1A1 and β-catenin and reduced the increase expression of PPAR-γ in trabecular bone.
-
SynonymsVerticinone | Raddeanine
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorOthers
-
Research AreaInflammation/Immunology
-
Indication——
Chemical Information
-
CAS Number18059-10-4
-
Formula Weight429.64
-
Molecular FormulaC27H43NO3
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 100 mg/mL; 232.75 mM
-
SMILESCC1CCC2C(C3CCC4C(C3CN2C1)CC5C4CC(=O)C6C5(CCC(C6)O)C)(C)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Lapatinib ditosylate...
Lapatinib ditosylate is an anti-Y drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung Y.
-
BMS-599626 hydrochlo...
BMS-599626 (AC-480) is a potent, selective inhibitor of EGFR and HER2 with IC50 of 20 nM and 30 nM.
-
Dihydroberberine
Dihydroberberine has anti-atherosclerotic anti-inflammatory hypolipidemic and antitumor activities. It inhibits human ether-a-go-go-related gene (hERG) channels and remarkably reduces Hsp90 expression and its interaction with hERG.
Cart
sales@molnova.com